WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac. Africa urgently needs 20 million second doses of COVID-19 vaccine
Africa needs at least 20 million doses of the Oxford-AstraZeneca vaccine in the next six weeks to get second doses to all who received a first dose within the 8 - 12-week interval between doses recommended by the World Health Organization (WHO). 60 million doses of COVID-19 vaccine administered in UK
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). First COVID-19 COVAX vaccine doses administered in Africa
The AMC is the COVAX Facility’s mechanism to provide donor-funded vaccines to lower-income countries.
COVAX announces new agreement, plans for first deliveries
More Pharma News ...
Business & Industry
- GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
- Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
- Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
- AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
- Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
Research & Development
- Thinking impaired in 60% of COVID-19 survivors
- Advantages of intranasal vaccination against SARS-CoV-2
- Antibiotics may help to treat melanoma
- Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
- Study shows why second dose of COVID-19 vaccine shouldn't be skipped
- Are silver nanoparticles a silver bullet against microbes?
- One shot of the Sputnik V vaccine triggers strong antibody responses
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA approves first interchangeable biosimilar insulin product for treatment of diabetes
- FDA approves first oral blood thinning medication for children
- FDA grants accelerated approval for Alzheimer's drug
- FDA approves new drug treatment for chronic weight management, first since 2014
- FDA authorizes additional monoclonal antibody for treatment of COVID-19